INTRODUCTION AND OBJECTIVES: Underdiagnosing malnutrition in high-risk surgical patients is problematic. Rapid skeletal muscle wasting is a serious and common complication following radical cystectomy (RC) to treat muscle-invasive bladder cancer. Specialized immunonutrition (SIM) intake before and after RC may help counteract muscle wasting in the post-operative period.
METHODS: Men with muscle-invasive cancer scheduled for radical cystectomy were randomly assigned to oral SIM providing supplemental L-arginine, fish oil, vitamin A, and nucleotides (n ¼ 14) or a calorie-and nitrogen-matched oral nutrition supplement [ONS (n ¼ 15)] for 5 days before and 5 days after RC. Malnutrition was assessed by a trained research team using the Patient-Generated Subjective Global Assessment (PG-SGA) tool. Dual Energy X-Ray Absorptiometry scans were obtained at baseline, 14 days, and 30 days after surgery to calculate relative skeletal muscle index (RSMI). Discrepancies between the malnutrition diagnoses using the PG-SGA tool and the UHC Billing database on the same patients were compared.
RESULTS: Using the PG-SGA tool, 21% of patients were identified as well nourished, 66% were moderately malnourished, and 14% were severely malnourished prior to RC. Billed and coded data showed 86% of patients were well nourished, 7% were moderately malnourished, and 7% were severely malnourished prior to RC. Relative Skeletal Muscle Index (RSMI) was better preserved in the SIM group at 14 days (7% vs. 17% in the ONS group).
CONCLUSIONS: The large discrepancy between patients identified as malnourished using the PG-SGA as compared to the billing data suggests a problem of underdiagnosing malnutrition in this population. Improving nutrition status through specialized immunonutrition could be a low risk, high-impact means of counteracting muscle wasting after RC for bladder cancer. Recent studies suggest that patients undergoing radical cystectomy (RC) for superficial bladder cancer that fails intravesical therapy (progressive muscle invasive disease, P-MIBC) do significantly worse than RC for de novo muscle invasive disease (DN-MIBC). We studied the impact of neoadjuvant (NAC) or adjuvant chemotherapy (AC) on survival in P-MIBC and DN-MIBC, using the Surveillance, Epidemiology, and End Results (SEER)-Medicare database.
METHODS: SEER-Medicare was used to identify patients from 2004-2011 who underwent RC for pT2-pT4 MIBC, and their patterns of NAC and AC use. P-MIBC patients were defined as those who were pT2-pT4 on RC pathology, with a history of Bacillus Calmette-Guerin therapy (BCG) or 3 transurethral resection of bladder tumor (TURBT). DN-MIBC patients were those with pT2-pT4 disease on RC pathology who had no history of BCG exposure or 2 TURBTs prior to RC. Kaplan Meier (KM) survival analysis and multivariable Cox models were used to compare overall survival (OS), cancer specific survival (CSS), and recurrence free survival (RFS) between P-MIBC and DN-MIBC patients who underwent RC with or without chemotherapy.
RESULTS: A total of 1,029 DN-MIBC and 97 P-MIBC patients undergoing RC were identified. Compared to DN-MIBC, P-MIBC patients had smaller primary tumors (p¼ 0.0009), lower cT stage (p¼ 0.0002), and AJCC stage (p¼ 0.0005). On KM analyses, P-MIBC patients had significantly worse OS (p ¼ 0.0048), RFS (p ¼ 0.0014), and nearly significantly worse CSS (p¼ 0.0724) compared to DN-MIBC (Fig.  1) . On multivariable analysis, older patients (>75 vs. 70 years, HR¼1.44, p<0.01), blacks (vs. white HR¼1.54, p¼0.036) and higher Charlson Deyo score (2 vs. 0, HR¼1.59, p<0.001) were associated with shorter OS. While OS, RFS and CSS were no longer significantly different between P-MIBC and DN-MIBC on multivariate analysis, NAC before RC was associated with significantly longer OS (HR¼0.71, p¼ 0.0150) compared to RC alone.
CONCLUSIONS: Progression to MIBC after intravesical therapy failure is associated with worse OS and RFS than DN-MIBC cases. Future studies may need to distinguish P-MIBC from DN-MIBC, as they appear to be biologically different, and NAC should be used more aggressively in the P-MIBC population before RC. METHODS: We evaluated data from 1,067 patients treated at a single institution with RC and pelvic lymph node dissection between 1990 and 2013 at a single institution tertiary care referral center. All specimen were evaluated by dedicated uropathologists. Univariable and multivariable Cox regression analyses tested the impact of the presence of pure and mixed histologic variants vs. pure urothelial and recurrence, CSM (cancer specific mortality) and OM (overall mortality) after accounting for all available confounders.
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